This is an old revision of this page, as edited by Beetstra (talk | contribs) at 09:29, 1 November 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: '').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 09:29, 1 November 2011 by Beetstra (talk | contribs) (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: '').)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | beta-amyloid |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C6552H10158N1730O2090S52 |
| Molar mass | 148.3 kDa g·mol |
| (what is this?) (verify) | |
Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.
Ponezumab was developed by Pfizer Inc.
References
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
| Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Bone |
| ||||||||
| Musculoskeletal |
| ||||||||
| Circulatory |
| ||||||||
| Neurologic |
| ||||||||
| Angiogenesis inhibitor |
| ||||||||
| Growth factor |
| ||||||||
| |||||||||
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |
 | This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |